{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:49:07Z","timestamp":1788997747044,"version":"build-2803163510"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s11910-022-01229-z","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T07:02:38Z","timestamp":1666854158000},"page":"721-734","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Bruton\u2019s Tyrosine Kinase Inhibition in Multiple Sclerosis"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1776-2418","authenticated-orcid":false,"given":"Raphael","family":"Schneider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"issue":"6","key":"1229_CR1","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000004977","volume":"90","author":"JF Sumowski","year":"2018","unstructured":"Sumowski JF, Benedict R, Enzinger C, Filippi M, Geurts JJ, Hamalainen P, et al. Cognition in multiple sclerosis: state of the field and priorities for the future. Neurology. 2018;90(6):278\u201388. https:\/\/doi.org\/10.1212\/WNL.0000000000004977.","journal-title":"Neurology"},{"key":"1229_CR2","unstructured":"Gilmour H, Ramage-Morin P, Wong S. Multiple sclerosis: prevalence and impact. 2018; Available from: https:\/\/www150.statcan.gc.ca\/n1\/en\/pub\/82-003-x\/2018001\/article\/54902-eng.pdf?st=8XxDG23O"},{"key":"1229_CR3","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12883-020-01772-7","volume":"20","author":"A Feinstein","year":"2020","unstructured":"Feinstein A, Amato MP, Brichetto G, Chataway J, Chiaravalloti N, Dalgas U, et al. Study protocol: improving cognition in people with progressive multiple sclerosis: a multi-arm, randomized, blinded, sham-controlled trial of cognitive rehabilitation and aerobic exercise (COGEx). Bmc Neurol. 2020;20:204.","journal-title":"Bmc Neurol"},{"key":"1229_CR4","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/WCO.0000000000001063","volume":"35","author":"BAC Cree","year":"2022","unstructured":"Cree BAC, Hartung H-P, Barnett M. New drugs for multiple sclerosis: new treatment algorithms. Curr Opin Neurol. 2022;35:262\u201370.","journal-title":"Curr Opin Neurol"},{"key":"1229_CR5","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. Jama Neurol. 2020;77:1132\u201340.","journal-title":"Jama Neurol"},{"key":"1229_CR6","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1002\/eji.201646485","volume":"46","author":"R Martin","year":"2016","unstructured":"Martin R, Sospedra M, Rosito M, Engelhardt B. Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis. Eur J Immunol. 2016;46:2078\u201390.","journal-title":"Eur J Immunol"},{"key":"1229_CR7","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1212\/WNL.0000000000003078","volume":"87","author":"L Kappos","year":"2016","unstructured":"Kappos L, Edan G, Freedman MS, Montalb\u00e1n X, Hartung H-P, Hemmer B, et al. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology. 2016;87:978\u201387.","journal-title":"Neurology"},{"key":"1229_CR8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ana.24747","volume":"80","author":"BAC Cree","year":"2016","unstructured":"Team: U of C San Francisco MS-EPIC, Cree BAC, Gourraud P-A, Oksenberg JR, Bevan C, Crabtree-Hartman E, et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016;80:499\u2013510.","journal-title":"Ann Neurol"},{"key":"1229_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jama.2018.20588","volume":"321","author":"JWL Brown","year":"2019","unstructured":"Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA. 2019;321:175.","journal-title":"JAMA"},{"key":"1229_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1177\/1352458519868990","volume":"26","author":"A Fambiatos","year":"2019","unstructured":"Fambiatos A, Jokubaitis V, Horakova D, Havrdova EK, Trojano M, Prat A, et al. Risk of secondary progressive multiple sclerosis: a longitudinal study. Mult Scler J. 2019;26:79\u201390.","journal-title":"Mult Scler J"},{"key":"1229_CR11","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1177\/1352458517709619","volume":"24","author":"L Kappos","year":"2017","unstructured":"Kappos L, Butzkueven H, Wiendl H, Spelman T, Pellegrini F, Chen Y, et al. Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Mult Scler J. 2017;24:963\u201373.","journal-title":"Mult Scler J"},{"key":"1229_CR12","doi-asserted-by":"publisher","first-page":"fcab229","DOI":"10.1093\/braincomms\/fcab229","volume":"3","author":"J Graf","year":"2021","unstructured":"Graf J, Leussink VI, Soncin G, Lepka K, Meinl I, K\u00fcmpfel T, et al. Relapse-independent multiple sclerosis progression under natalizumab. Brain Commun. 2021;3:fcab229.","journal-title":"Brain Commun"},{"key":"1229_CR13","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1136\/annrheumdis-2013-204143","volume":"74","author":"LM Hartkamp","year":"2015","unstructured":"Hartkamp LM, Fine JS, van Es IE, Tang MW, Smith M, Woods J, et al. Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants. Ann Rheum Dis. 2015;74:1603.","journal-title":"Ann Rheum Dis"},{"key":"1229_CR14","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/art.40059","volume":"69","author":"OBJ Corneth","year":"2017","unstructured":"Corneth OBJ, Verstappen GMP, Paulissen SMJ, de Bruijn MJW, Rip J, Lukkes M, et al. Enhanced Bruton\u2019s Tyrosine Kinase Activity in peripheral blood B lymphocytes from patients with autoimmune disease. Arthritis Rheumatol. 2017;69:1313\u201324.","journal-title":"Arthritis Rheumatol"},{"key":"1229_CR15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00401-020-02204-z","volume":"140","author":"S Torke","year":"2020","unstructured":"Torke S, Pretzsch R, H\u00e4usler D, Haselmayer P, Grenningloh R, Boschert U, et al. Inhibition of Bruton\u2019s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease. Acta Neuropathol. 2020;140:535\u201348.","journal-title":"Acta Neuropathol"},{"key":"1229_CR16","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrc3702","volume":"14","author":"RW Hendriks","year":"2014","unstructured":"Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton\u2019s tyrosine kinase in B cell malignancies. Nat Rev Cancer. 2014;14:219\u201332.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"1229_CR17","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/art.41275","volume":"72","author":"S Cohen","year":"2020","unstructured":"Cohen S, Tuckwell K, Katsumoto TR, Zhao R, Galanter J, Lee C, et al. Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study). Arthritis Rheumatol Hoboken N J. 2020;72(9):1435\u201346.","journal-title":"Arthritis Rheumatol Hoboken N J"},{"key":"1229_CR18","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/art.41811","volume":"73","author":"D Isenberg","year":"2021","unstructured":"Isenberg D, Furie R, Jones NS, Guibord P, Galanter J, Lee C, et al. Efficacy, Safety, and Pharmacodynamic Effects of the Bruton\u2019s Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol Hoboken N J. 2021;73:1835\u201346.","journal-title":"Arthritis Rheumatol Hoboken N J"},{"key":"1229_CR19","doi-asserted-by":"publisher","unstructured":"Turner TJ, Brun P, Ofengheim D, Gruber R. Comparative CNS pharmacology of tolebrutinib versus other BTK inhibitor candidates for treating.\u00a0Mult Scler J. 2022;\u00a028(1_suppl):1\u20132. https:\/\/doi.org\/10.1177\/13524585221094743.","DOI":"10.1177\/13524585221094743"},{"key":"1229_CR20","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1474-4422(15)00334-8","volume":"15","author":"R Hohlfeld","year":"2016","unstructured":"Hohlfeld R, Dornmair K, Meinl E, Wekerle H. The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets. Lancet Neurol. 2016;15:198\u2013209.","journal-title":"Lancet Neurol"},{"key":"1229_CR21","doi-asserted-by":"publisher","first-page":"7188","DOI":"10.1126\/science.aav7188","volume":"365","author":"Consortium*\u2020 IMSG","year":"2019","unstructured":"Consortium*\u2020 IMSG. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019;365:7188.","journal-title":"Science"},{"key":"1229_CR22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1750-3639.1996.tb00854.x","volume":"6","author":"CF Lucchinetti","year":"1996","unstructured":"Lucchinetti CF, Br\u00fcck W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol. 1996;6:259\u201374.","journal-title":"Brain Pathol"},{"key":"1229_CR23","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1056\/NEJM199801293380502","volume":"338","author":"BD Trapp","year":"1998","unstructured":"Trapp BD, Peterson J, Ransohoff RM, Rudick R, M\u00f6rk S, B\u00f6 L. Axonal transection in the lesions of multiple sclerosis. New Engl J Med. 1998;338:278\u201385.","journal-title":"New Engl J Med"},{"key":"1229_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-94-017-9487-9_2","volume":"841","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Zhang Y, Gu W, Sun B. Advances in experimental medicine and biology. Adv Exp Med Biol. 2014;841:15\u201344.","journal-title":"Adv Exp Med Biol"},{"key":"1229_CR25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.1750-3639.2004.tb00049.x","volume":"14","author":"B Serafini","year":"2004","unstructured":"Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004;14:164\u201374.","journal-title":"Brain Pathol"},{"key":"1229_CR26","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1093\/brain\/aws189","volume":"135","author":"SR Choi","year":"2012","unstructured":"Choi SR, Howell OW, Carassiti D, Magliozzi R, Gveric D, Muraro PA, et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain. 2012;135:2925\u201337.","journal-title":"Brain"},{"key":"1229_CR27","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/brain\/awm038","volume":"130","author":"R Magliozzi","year":"2006","unstructured":"Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2006;130:1089\u2013104.","journal-title":"Brain"},{"key":"1229_CR28","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1093\/brain\/awr182","volume":"134","author":"OW Howell","year":"2011","unstructured":"Howell OW, Reeves CA, Nicholas R, Carassiti D, Radotra B, Gentleman SM, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain. 2011;134:2755\u201371.","journal-title":"Brain"},{"key":"1229_CR29","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/ana.21939","volume":"67","author":"A Bar-Or","year":"2010","unstructured":"Bar-Or A, Fawaz L, Fan B, Darlington PJ, Rieger A, Ghorayeb C, et al. Abnormal B-cell cytokine responses a trigger of T-cell\u2013mediated disease in MS? Ann Neurol. 2010;67:452\u201361.","journal-title":"Ann Neurol"},{"issue":"187","key":"1229_CR30","first-page":"4119","volume":"2011","author":"R Schneider","year":"1950","unstructured":"Schneider R, Mohebiany AN, Ifergan I, Beauseigle D, Duquette P, Prat A, et al. B cell-derived IL-15 enhances CD8 T cell cytotoxicity and is increased in multiple sclerosis patients. J Immunol Baltim Md. 1950;2011(187):4119\u201328.","journal-title":"J Immunol Baltim Md"},{"key":"1229_CR31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.clim.2016.10.001","volume":"173","author":"J Fraussen","year":"2016","unstructured":"Fraussen J, Claes N, Wijmeersch BV, van Horssen J, Stinissen P, Hupperts R, et al. B cells of multiple sclerosis patients induce autoreactive proinflammatory T cell responses. Clin Immunol Orlando Fla. 2016;173:124\u201332.","journal-title":"Clin Immunol Orlando Fla"},{"key":"1229_CR32","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","volume":"378","author":"L Kappos","year":"2011","unstructured":"Kappos L, Li D, Calabresi PA, O\u2019Connor P, Bar-Or A, Barkhof F, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378:1779\u201387.","journal-title":"Lancet"},{"key":"1229_CR33","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","volume":"87","author":"J Salzer","year":"2016","unstructured":"Salzer J, Svenningsson R, Alping P, Novakova L, Bj\u00f6rck A, Fink K, et al. Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology. 2016;87:2074\u201381.","journal-title":"Neurology"},{"key":"1229_CR34","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. New Engl J Medicine. 2017;376:209\u201320.","journal-title":"New Engl J Medicine"},{"key":"1229_CR35","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, et al. Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis. New Engl J Medicine. 2017;376:221\u201334.","journal-title":"New Engl J Medicine"},{"key":"1229_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ebiom.2017.01.042","volume":"16","author":"D Baker","year":"2017","unstructured":"Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K. Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. EBioMedicine. 2017;16:41\u201350.","journal-title":"EBioMedicine"},{"key":"1229_CR37","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1177\/1352458520949986","volume":"27","author":"NG Caldito","year":"2020","unstructured":"Caldito NG, Shirani A, Salter A, Stuve O. Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database. Mult Scler J. 2020;27:1066\u201376.","journal-title":"Mult Scler J"},{"key":"1229_CR38","doi-asserted-by":"publisher","first-page":"e1870","DOI":"10.1212\/WNL.0000000000012753","volume":"97","author":"S Simpson-Yap","year":"2021","unstructured":"Simpson-Yap S, Brouwer ED, Kalincik T, Rijke N, Hillert JA, Walton C, et al. Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology. 2021;97:e1870\u201385.","journal-title":"Neurology"},{"key":"1229_CR39","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1093\/brain\/awaa158","volume":"143","author":"K J\u00e4ckle","year":"2020","unstructured":"J\u00e4ckle K, Zeis T, Schaeren-Wiemers N, Junker A, van der Meer F, Kramann N, et al. Molecular signature of slowly expanding lesions in progressive multiple sclerosis. Brain. 2020;143:2073\u201388.","journal-title":"Brain"},{"key":"1229_CR40","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41586-021-03892-7","volume":"597","author":"M Absinta","year":"2021","unstructured":"Absinta M, Maric D, Gharagozloo M, Garton T, Smith MD, Jin J, et al. A lymphocyte\u2013microglia\u2013astrocyte axis in chronic active multiple sclerosis. Nature. 2021;597:709\u201314.","journal-title":"Nature"},{"key":"1229_CR41","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1172\/JCI86198","volume":"126","author":"M Absinta","year":"2016","unstructured":"Absinta M, Sati P, Schindler M, Leibovitch EC, Ohayon J, Wu T, et al. Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions. J Clin Invest. 2016;126:2597\u2013609.","journal-title":"J Clin Invest"},{"key":"1229_CR42","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1001\/jamaneurol.2019.2399","volume":"76","author":"M Absinta","year":"2019","unstructured":"Absinta M, Sati P, Masuzzo F, Nair G, Sethi V, Kolb H, et al. Association of chronic active multiple sclerosis lesions with disability in vivo. Jama Neurol. 2019;76:1474\u201383.","journal-title":"Jama Neurol"},{"key":"1229_CR43","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1093\/brain\/awz212","volume":"142","author":"C Elliott","year":"2019","unstructured":"Elliott C, Belachew S, Wolinsky JS, Hauser SL, Kappos L, Barkhof F, et al. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain. 2019;142:2787\u201399.","journal-title":"Brain"},{"key":"1229_CR44","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/ana.25877","volume":"88","author":"P Maggi","year":"2020","unstructured":"Maggi P, Sati P, Nair G, Cortese ICM, Jacobson S, Smith BR, et al. Paramagnetic Rim Lesions are Specific to Multiple Sclerosis: An International Multicenter 3T MRI Study. Ann Neurol. 2020;88:1034\u201342.","journal-title":"Ann Neurol"},{"key":"1229_CR45","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001139","volume":"9","author":"P Preziosa","year":"2022","unstructured":"Preziosa P, Pagani E, Meani A, Moiola L, Rodegher M, Filippi M, et al. Slowly expanding lesions predict 9-year multiple sclerosis disease progression. Neurol-Neuroimmunol Neuroinflamm. 2022;9: e1139.","journal-title":"Neurol-Neuroimmunol Neuroinflamm"},{"key":"1229_CR46","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1001\/jamaneurol.2020.0124","volume":"77","author":"S Suthiphosuwan","year":"2020","unstructured":"Suthiphosuwan S, Sati P, Absinta M, Guenette M, Reich DS, Bharatha A, et al. Paramagnetic rim sign in radiologically isolated syndrome. Jama Neurol. 2020;77:653.","journal-title":"Jama Neurol"},{"issue":"14","key":"1229_CR47","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1177\/13524585211002097","volume":"27","author":"J Oh","year":"2021","unstructured":"Oh J, Suthiphosuwan S, Sati P, Absinta M, Dewey B, Guenette M, et al. Cognitive impairment, the central vein sign, and paramagnetic rim lesions in RIS. Mult Scler J. 2021;27(14):2199\u2013208.","journal-title":"Mult Scler J"},{"key":"1229_CR48","doi-asserted-by":"publisher","first-page":"4411","DOI":"10.1038\/s41598-022-08477-6","volume":"12","author":"M Marcille","year":"2022","unstructured":"Marcille M, R\u00faa SH, Tyshkov C, Jaywant A, Comunale J, Kaunzner UW, et al. Disease correlates of rim lesions on quantitative susceptibility mapping in multiple sclerosis. Sci Rep-uk. 2022;12:4411.","journal-title":"Sci Rep-uk"},{"issue":"27","key":"1229_CR49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/13524585211044647","volume":"2021","author":"ECTRIMS","year":"2021","unstructured":"ECTRIMS. Oral Presentations. Mult Scler J. 2021;2021(27):3\u2013133. https:\/\/doi.org\/10.1177\/13524585211044647.","journal-title":"Mult Scler J"},{"key":"1229_CR50","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S1474-4422(21)00237-4","volume":"20","author":"DS Reich","year":"2021","unstructured":"\u2022\u2022 Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, et al. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021;20:729\u201338.  Phase II clinical trial with unique study design that met the primary endpoint of reduction in gadolinium-enhancing lesions in the brain of pwMS receiving Tolebrutinib at 60 mg daily.","journal-title":"Lancet Neurol"},{"key":"1229_CR51","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00401-022-02411-w","volume":"143","author":"R Li","year":"2022","unstructured":"\u2022 Li R, Tang H, Burns JC, Hopkins BT, Coz CL, Zhang B, et al. BTK inhibition limits B-cell\u2013T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy. Acta Neuropathol. 2022;143:505\u201321.  Study showing that Evobrutinib impairs the capacity of B-cells to act as antigen-presenting cells for the development of encephalitogenic T cells.","journal-title":"Acta Neuropathol"},{"key":"1229_CR52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14728214.2020.1729121","volume":"25","author":"EC Contentti","year":"2020","unstructured":"Contentti EC, Correale J. Bruton\u2019s tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis. Expert Opin Emerg Dr. 2020;25:1\u20135.","journal-title":"Expert Opin Emerg Dr"},{"key":"1229_CR53","doi-asserted-by":"publisher","unstructured":"Rijvers L, Langelaar J van, Bogers L, Melief M-J, Koetzier SC, Blok KM, et al. Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinib. Jci Insight.\u00a02022;7(16):e160909. https:\/\/doi.org\/10.1172\/jci.insight.160909.","DOI":"10.1172\/jci.insight.160909"},{"key":"1229_CR54","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/leu.2015.316","volume":"30","author":"S-S Chen","year":"2016","unstructured":"Chen S-S, Chang BY, Chang S, Tong T, Ham S, Sherry B, et al. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia. 2016;30:833\u201343.","journal-title":"Leukemia"},{"key":"1229_CR55","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.clim.2007.10.005","volume":"126","author":"H Taneichi","year":"2008","unstructured":"Taneichi H, Kanegane H, Sira MM, Futatani T, Agematsu K, Sako M, et al. Toll-like receptor signaling is impaired in dendritic cells from patients with X-linked agammaglobulinemia. Clin Immunol. 2008;126:148\u201354.","journal-title":"Clin Immunol"},{"key":"1229_CR56","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.3389\/fimmu.2017.01454","volume":"8","author":"ANR Weber","year":"2017","unstructured":"Weber ANR, Bittner Z, Liu X, Dang T-M, Radsak MP, Brunner C. Bruton\u2019s Tyrosine Kinase: an emerging key player in innate immunity. Front Immunol. 2017;8:1454.","journal-title":"Front Immunol"},{"key":"1229_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.668131","volume":"9","author":"SFH Neys","year":"2021","unstructured":"Neys SFH, Hendriks RW, Corneth OBJ. Targeting Bruton\u2019s Tyrosine kinase in inflammatory and autoimmune pathologies. Front Cell Dev Biol. 2021;9: 668131.","journal-title":"Front Cell Dev Biol"},{"key":"1229_CR58","doi-asserted-by":"publisher","unstructured":"Alankus YB, Grenningloh R, Haselmayer P, Bender A, Bruttger J. Inhibition of Bruton\u2019s Tyrosine Kinase prevents inflammatory macrophage differentiation: a potential role in multiple sclerosis (P2. 2\u2013077).\u00a0AAN Enterprises. Lupus Science Medicine. 2019; 6. https:\/\/doi.org\/10.1136\/lupus-2019-lsm.216.","DOI":"10.1136\/lupus-2019-lsm.216"},{"key":"1229_CR59","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.molmed.2018.11.005","volume":"25","author":"S Voet","year":"2019","unstructured":"Voet S, Prinz M, van Loo G. Microglia in central nervous system inflammation and multiple sclerosis pathology. Trends Mol Med. 2019;25:112\u201323.","journal-title":"Trends Mol Med"},{"key":"1229_CR60","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12974-018-1308-0","volume":"15","author":"HY Nam","year":"2018","unstructured":"Nam HY, Nam JH, Yoon G, Lee J-Y, Nam Y, Kang H-J, et al. Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice. J Neuroinflamm. 2018;15:271.","journal-title":"J Neuroinflamm"},{"key":"1229_CR61","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3233\/BPL-200100","volume":"5","author":"E Martin","year":"2020","unstructured":"Martin E, Aigrot M-S, Grenningloh R, Stankoff B, Lubetzki C, Boschert U, et al. Bruton\u2019s Tyrosine Kinase inhibition promotes myelin repair. Brain Plasticity Amsterdam Neth. 2020;5:123\u201333.","journal-title":"Brain Plasticity Amsterdam Neth"},{"key":"1229_CR62","doi-asserted-by":"crossref","unstructured":"Gruber R, Blazier A, Lee L, Ryan S, Cheong A, Havari E, et al. Evaluating the effect of BTK inhibitor tolebrutinib in human tri-culture (P1\u20131. Virtual). AAN Enterprises.\u00a0Neurology. 2022;98(18 Supplement):2594.","DOI":"10.1212\/WNL.98.18_supplement.2594"},{"key":"1229_CR63","doi-asserted-by":"publisher","first-page":"7643","DOI":"10.1021\/acs.jmedchem.9b00794","volume":"62","author":"RD Caldwell","year":"2019","unstructured":"Caldwell RD, Qiu H, Askew BC, Bender AT, Brugger N, Camps M, et al. Discovery of evobrutinib: an oral, potent, and highly selective, Covalent Bruton\u2019s Tyrosine Kinase (BTK) inhibitor for the treatment of immunological diseases. J Med Chem. 2019;62:7643\u201355.","journal-title":"J Med Chem"},{"key":"1229_CR64","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/cts.12713","volume":"13","author":"A Becker","year":"2018","unstructured":"Becker A, Martin EC, Mitchell DY, Grenningloh R, Bender AT, Laurent J, et al. Safety, Tolerability, pharmacokinetics, target occupancy, and concentration-QT analysis of the Novel BTK inhibitor evobrutinib in healthy volunteers. Clin Transl Sci. 2018;13:325\u201336.","journal-title":"Clin Transl Sci"},{"key":"1229_CR65","doi-asserted-by":"crossref","unstructured":"Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Martin EC, et al. Evobrutinib efficacy is maintained over two years in an open-label phase II study extension in patients with relapsing multiple sclerosis (4124). 96:4124. Available from: http:\/\/n.neurology.org\/content\/96\/15_Supplement\/4124.abstract","DOI":"10.1212\/WNL.96.15_supplement.4124"},{"key":"1229_CR66","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/cts.13162","volume":"15","author":"TD Owens","year":"2021","unstructured":"Owens TD, Smith PF, Redfern A, Xing Y, Shu J, Karr DE, et al. Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168). Clin Transl Sci. 2021;15:442\u201350.","journal-title":"Clin Transl Sci"},{"key":"1229_CR67","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1038\/s41591-021-01537-w","volume":"27","author":"M Metz","year":"2021","unstructured":"Metz M, Sussman G, Gagnon R, Staubach P, Tanus T, Yang WH, et al. Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial. Nat Med. 2021;27:1961\u20139.","journal-title":"Nat Med"},{"key":"1229_CR68","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1021\/acs.jmedchem.7b01712","volume":"61","author":"JJ Crawford","year":"2018","unstructured":"Crawford JJ, Johnson AR, Misner DL, Belmont LD, Castanedo G, Choy R, et al. Discovery of GDC-0853: a potent, selective, and noncovalent Bruton\u2019s Tyrosine Kinase Inhibitor in early clinical development. J Med Chem. 2018;61:2227\u201345.","journal-title":"J Med Chem"},{"key":"1229_CR69","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/cpt.1056","volume":"103","author":"AE Herman","year":"2018","unstructured":"Herman AE, Chinn LW, Kotwal SG, Murray ER, Zhao R, Florero M, et al. Safety, pharmacokinetics, and pharmacodynamics in healthy volunteers treated with GDC-0853, a selective reversible Bruton\u2019s Tyrosine Kinase Inhibitor. Clin Pharmacol Ther. 2018;103:1020\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"1229_CR70","doi-asserted-by":"publisher","first-page":"5102","DOI":"10.1021\/acs.jmedchem.9b01916","volume":"63","author":"D Angst","year":"2020","unstructured":"Angst D, Gessier F, Janser P, Vulpetti A, W\u00e4lchli R, Beerli C, et al. Discovery of LOU064 (Remibrutinib), a potent and highly selective covalent inhibitor of Bruton\u2019s Tyrosine Kinase. J Med Chem. 2020;63:5102\u201318.","journal-title":"J Med Chem"},{"key":"1229_CR71","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1111\/cts.13005","volume":"14","author":"M Kaul","year":"2021","unstructured":"Kaul M, End P, Cabanski M, Schuhler C, Jakab A, Kistowska M, et al. Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. Clin Transl Sci. 2021;14:1756\u201368.","journal-title":"Clin Transl Sci"},{"key":"1229_CR72","doi-asserted-by":"crossref","unstructured":"Wiendl H, Airas L, Chitnis T, Williams M, Nakahara J, Bermel R, et al. Phase 3 REMODEL I\/II trials: effectiveness, safety, and tolerability of remibrutinib in patients with relapsing multiple sclerosis (P7\u20134.003). 98:2562. Available from: http:\/\/n.neurology.org\/content\/98\/18_Supplement\/2562.abstract","DOI":"10.1212\/WNL.98.18_supplement.2562"},{"key":"1229_CR73","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-021-01049-7","volume":"14","author":"D Gu","year":"2021","unstructured":"Gu D, Tang H, Wu J, Li J, Miao Y. Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies. J Hematol Oncol. 2021;14:40.","journal-title":"J Hematol Oncol"},{"key":"1229_CR74","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40265-021-01482-5","volume":"81","author":"DS Orelabrutinib","year":"2021","unstructured":"Orelabrutinib DS. First Approval. Drugs. 2021;81:503\u20137.","journal-title":"Drugs"},{"key":"1229_CR75","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1212\/CPJ.0000000000000567","volume":"9","author":"EJ Fox","year":"2019","unstructured":"Fox EJ, Buckle GJ, Singer B, Singh V, Boster A. Lymphopenia and DMTs for relapsing forms of MS: considerations for the treating neurologist. Neurology Clin Pract. 2019;9:53\u201363.","journal-title":"Neurology Clin Pract"},{"key":"1229_CR76","doi-asserted-by":"publisher","first-page":"AB16","DOI":"10.1016\/j.jaci.2018.12.051","volume":"143","author":"L Tsao","year":"2019","unstructured":"Tsao L, Otani IM, Bove R. Hypogammaglobulinemia in multiple sclerosis patients receiving disease-modifying immunomodulatory agents. J Allergy Clin Immun. 2019;143:AB16.","journal-title":"J Allergy Clin Immun"},{"key":"1229_CR77","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. New Engl J Medicine. 2012;366:1870\u201380.","journal-title":"New Engl J Medicine"},{"key":"1229_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.630942","volume":"9","author":"HY Estupi\u00f1\u00e1n","year":"2021","unstructured":"Estupi\u00f1\u00e1n HY, Bergl\u00f6f A, Zain R, Smith CIE. Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol. 2021;9: 630942.","journal-title":"Front Cell Dev Biol"},{"key":"1229_CR79","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","volume":"380","author":"X Montalban","year":"2019","unstructured":"\u2022\u2022 Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, et al. Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis. New Engl J Med. 2019;380:2406\u201317.  First phase II clinical trial that demonstrated efficacy of a BTKI in MS. This study met the primary endpoint of reduction in gadolinium-enhancing lesions in the brain of pwMS receiving Evobrutinib at 75 mg daily.","journal-title":"New Engl J Med"},{"key":"1229_CR80","first-page":"13","volume":"16","author":"J Oh","year":"2022","unstructured":"Oh J, Fox RJ, Arnold DL, Syed S, Orogun L, Dukovic D, et al. MRI, safety, and efficacy outcomes in patients with relapsing MS: 18-month results from the long-term extension study of tolebrutinib. Headache. 2022;16:13.","journal-title":"Headache"},{"key":"1229_CR81","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1182\/bloodadvances.2019001319","volume":"4","author":"HY Estupi\u00f1\u00e1n","year":"2020","unstructured":"Estupi\u00f1\u00e1n HY, Bouderlique T, He C, Bergl\u00f6f A, Gupta D, Saher O, et al. Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects. Blood Adv. 2020;4:2439\u201350.","journal-title":"Blood Adv"},{"issue":"27","key":"1229_CR82","first-page":"134","volume":"2021","author":"ECTRIMS","year":"2021","unstructured":"ECTRIMS. \u2013 ePoster. Mult Scler J. 2021;2021(27):134\u2013740.","journal-title":"Mult Scler J"},{"key":"1229_CR83","unstructured":"Sanofi. Patient enrollment of phase III tolebrutinib trials paused in the U.S.\u00a02022.\u00a0https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2022\/2022-06-30-05-30-00-2471767."},{"key":"1229_CR84","doi-asserted-by":"crossref","unstructured":"Oh J, Cohen S, Isenberg D, Maurer M, Galanter J, Chu T, et al. The safety of fenebrutinib in a large population of patients with diverse autoimmune indications supports investigation in multiple sclerosis (MS)(4564). AAN Enterprises.\u00a0Neurology. 2021;96(15 Supplement):4564.","DOI":"10.1212\/WNL.96.15_supplement.4564"},{"key":"1229_CR85","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1200\/JCO.21.00693","volume":"39","author":"H Abdel-Qadir","year":"2021","unstructured":"Abdel-Qadir H, Sabrie N, Leong D, Pang A, Austin PC, Prica A, et al. Cardiovascular risk associated with ibrutinib use in chronic lymphocytic leukemia: a population-based cohort study. J Clin Oncol Official J Am Soc Clin Oncol. 2021;39:3453\u201362.","journal-title":"J Clin Oncol Official J Am Soc Clin Oncol"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-022-01229-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-022-01229-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-022-01229-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T14:06:17Z","timestamp":1744207577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-022-01229-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":85,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["1229"],"URL":"https:\/\/doi.org\/10.1007\/s11910-022-01229-z","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]},"assertion":[{"value":"7 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Raphael Schneider received grants from the MS Society of Canada and the J.P. Bickell Foundation. Dr. Schneider has received consulting fees from Biogen-Idec and Novartis. Dr. Schneider has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Biogen-Idec, Sanofi-Genzyme, and EMD-Serono. Dr. Schneider has participated on advisory boards for Novartis and BMS. Dr. Schneider has received support to attend a scientific meeting from EMD-Serono. He is on the editorial board of Frontiers in Neurology.Dr. Jiwon Oh has received grants from the MS Society of Canada, Biogen-Idec, Brain Canada, Roche, the NIH, and EMD-Serono. Dr. Oh has received consulting fees from Biogen-Idec, BMS, Sanofi-Genzyme, Novartis, EMD-Serono,Eli Lilly, and Roche. Dr. Oh has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Biogen-Idec, Roche, Sanofi-Genzyme, Novartis, and EMD-Serono. Dr. Oh has participated on advisory boards for Sanofi-Genzyme, EMD-Serono, Roche, Novartis, Biogen-Idec, and BMS. She is the MS Society of Canada Medical Advisory Committee Chair.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}